Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Sep 24, 2024 (2 years ago)

Dapsone Gel 7.5%

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Crystallization

Cause type: Failed specification

A physical or chemical test other than potency, dissolution, impurity or stability failed - pH, viscosity, appearance, tablet integrity, fill volume. A product outside its own specification may not perform as designed, even if the active ingredient is present. All failed specification recalls.

What was recalled

Dapsone Gel 7.5%, 60 gram pump, Rx Only, Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India, Distributed by: Viona Pharmaceuticals Inc., Cranford, NJ 07016, NDC 72578-094-02.

Affected NDC 72578-0094-02

Compare with the code on your package — it is the most precise check available.

Drug: Dapsone

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Dapsone
NDC 72578-0094
75 mg/g Gel
Topical
Viona Pharmaceuticals Inc Rx
Recalling firm
Viona Pharmaceuticals INC
NDC code
72578-094-02
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0011-2025 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Dapsone recalls

See all

Other recalls by Viona Pharmaceuticals INC

All 2024 recalls